|
1
|
Moran AE, Forouzanfar MH, Roth GA, Mensah
GA, Ezzati M, Flaxman A, Murray CJ and Naghavi M: The global burden
of ischemic heart disease in 1990 and 2010: The global burden of
disease 2010 study. Circulation. 129:1493–1501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miura T and Miki T: Limitation of
myocardial infarct size in the clinical setting: Current status and
challenges in translating animal experiments into clinical therapy.
Basic Res Cardiol. 103:501–513. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eltzschig HK and Eckle T: Ischemia and
reperfusion-from mechanism to translation. Nat Med. 17:1391–1401.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Li Z, Zhang C, Li P, Wu Y, Wang C,
Bond Lau W, Ma XL and Du J: Cardiac fibroblast-specific activating
transcription factor 3 protects against heart failure by
suppressing MAP2K3-p38 signaling. Circulation. 135:2041–2057. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krum H and Teerlink JR: Medical therapy
for chronic heart failure. Lancet. 378:713–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kloner RA: Current state of clinical
translation of cardioprotective agents for acute myocardial
infarction. Circ Res. 113:451–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gerczuk PZ and Kloner RA: An update on
cardioprotection: A review of the latest adjunctive therapies to
limit myocardial infarction size in clinical trials. J Am Coll
Cardiol. 59:969–978. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arkin MR and Wells JA: Small-molecule
inhibitors of protein-protein interactions: Progressing towards the
dream. Nat Rev Drug Discov. 3:301–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kumphune S, Chattipakorn S and
Chattipakorn N: Role of p38 inhibition in cardiac
ischemia/reperfusion injury. Eur J Clin Pharmacol. 68:513–524.
2012. View Article : Google Scholar
|
|
10
|
Prompunt E, Sanit J, Barrère-Lemaire S,
Nargeot J, Noordali H, Madhani M and Kumphune S: The
cardioprotective effects of secretory leukocyte protease inhibitor
against myocardial ischemia/reperfusion injury. Exp Ther Med.
15:5231–5242. 2018.PubMed/NCBI
|
|
11
|
Cai Y, Lu C, Xu T, Ma Y, Min S, Scammells
P, Wang B and Ju S: Diffusion tensor imaging evaluation of
axonal/white matter remodeling in a mouse model of diabetic stroke
treated with novel p38 MAPK inhibitor, VCP979. J Biomed
Nanotechnol. 14:585–593. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vinh NB, Devine SM, Munoz L, Ryan RM, Wang
BH, Krum H, Chalmers DK, Simpson JS and Scammells PJ: Design,
synthesis, and biological evaluation of tetra-substituted
thiophenes as inhibitors of p38α MAPK. ChemistryOpen. 4:56–64.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu T, Ding J, Ge H, Xu X, Scammells P,
Wang B and Ju S: Effects of VCP979 novel p38 mitogen activated
protein kinase inhibitor on progression of pancreatic cancer in
mouse model with diabetic conditions. J Biomed Nanotechnol.
15:1325–1333. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan D, Tie J, Xu Z, Liu G, Ge X, Wang Z,
Zhang X, Gong S, Liu G, Meng Q, et al: Dynamic profile of CD4(+)
T-cell- associated cytokines/chemokines following murine myocardial
infarction/reperfusion. Mediators Inflamm. 2019:94836472019.
View Article : Google Scholar
|
|
15
|
Yang L, Wang B, Zhou Q, Wang Y, Liu X, Liu
Z and Zhan Z: MicroRNA-21 prevents excessive inflammation and
cardiac dysfunction after myocardial infarction through targeting
KBTBD7. Cell Death Dis. 9:7692018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu J, Ye Q, Xu S, Chang YX, Liu X, Ma Y,
Zhu Y and Hua S: Shengmai injection alleviates H2O2 induced
oxidative stress through activation of AKT and inhibition of ERK
pathways in neonatal rat cardiomyocytes. J Ethnopharmacol.
239:1116772019. View Article : Google Scholar
|
|
17
|
Dolber PC, Beyer EC, Junker JL and Spach
MS: Distribution of gap junctions in dog and rat ventricle studied
with a double-label technique. J Mol Cell Cardiol. 24:1443–1457.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhuang R, Wu J, Lin F, Han L, Liang X,
Meng Q, Jiang Y, Wang Z, Yue A, Gu Y, et al: Fasudil preserves lung
endothelial function and reduces pulmonary vascular remodeling in a
rat model of endstage pulmonary hypertension with left heart
disease. Int J Mol Med. 42:1341–1352. 2018.PubMed/NCBI
|
|
19
|
Dick SA and Epelman S: Chronic heart
failure and inflammation: What do we really know? Circ Res.
119:159–176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tamargo J, Caballero R and Delpón E: New
drugs in preclinical and early stage clinical development in the
treatment of heart failure. Expert Opin Investig Drugs. 28:51–71.
2019. View Article : Google Scholar
|
|
21
|
Lemke LE, Bloem LJ, Fouts R, Esterman M,
Sandusky G and Vlahos CJ: Decreased p38 MAPK activity in end-stage
failing human myocardium: p38 MAPK alpha is the predominant isoform
expressed in human heart. J Mol Cell Cardiol. 33:1527–1540. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shinde AV and Frangogiannis NG:
Fibroblasts in myocardial infarction: A role in inflammation and
repair. J Mol Cell Cardiol. 70:74–82. 2014. View Article : Google Scholar
|
|
23
|
Kaur H, Takefuji M, Ngai CY, Carvalho J,
Bayer J, Wietelmann A, Poetsch A, Hoelper S, Conway SJ, Möllmann H,
et al: Targeted ablation of periostin-expressing activated
fibroblasts prevents adverse cardiac remodeling in mice. Circ Res.
118:1906–1917. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma Y, Hu Y, Wu J, Wen J, Li S, Zhang L,
Zhang J, Li Y and Li J: Epigallocatechin-3-gallate inhibits
angiotensin II-induced cardiomyocyte hypertrophy via regulating
Hippo signaling pathway in H9c2 rat cardiomyocytes. Acta Biochim
Biophys Sin (Shanghai). 51:422–430. 2019. View Article : Google Scholar
|
|
25
|
French BA and Kramer CM: Mechanisms of
post-infarct left ventricular remodeling. Drug Discov Today Dis
Mech. 4:185–196. 2007. View Article : Google Scholar
|
|
26
|
Kompa AR, See F, Lewis DA, Adrahtas A,
Cantwell DM, Wang BH and Krum H: Long-term but not short-term p38
mitogen-activated protein kinase inhibition improves cardiac
function and reduces cardiac remodeling post-myocardial infarction.
J Pharmacol Exp Ther. 325:741–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Napoli P, Taccardi AA, De Caterina R
and Barsotti A: Pathophysiology of ischemia-reperfusion injury:
Experimental data. Ital Heart J. 3(Suppl 4): 24s–28s.
2002.PubMed/NCBI
|
|
28
|
Hofmann U and Frantz S: Role of
lymphocytes in myocardial injury, healing, and remodeling after
myocardial infarction. Circ Res. 116:354–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hofmann U, Beyersdorf N, Weirather J,
Podolskaya A, Bauersachs J, Ertl G, Kerkau T and Frantz S:
Activation of CD4+ T lymphocytes improves wound healing and
survival after experimental myocardial infarction in mice.
Circulation. 125:1652–1663. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boag SE, Andreano E and Spyridopoulos I:
Lymphocyte communication in myocardial ischemia/reperfusion injury.
Antioxid Redox Signal. 26:660–675. 2017. View Article : Google Scholar
|
|
31
|
Hofmann U and Frantz S: Role of T-cells in
myocardial infarction. Eur Heart J. 37:873–879. 2016. View Article : Google Scholar
|
|
32
|
Stabile E, Kinnaird T, la Sala A, Hanson
SK, Watkins C, Campia U, Shou M, Zbinden S, Fuchs S, Kornfeld H, et
al: CD8+ T lymphocytes regulate the arteriogenic response to
ischemia by infiltrating the site of collateral vessel development
and recruiting CD4+ mononuclear cells through the expression of
interleukin-16. Circulation. 113:118–124. 2006. View Article : Google Scholar
|
|
33
|
Varda-Bloom N, Leor J, Ohad DG, Hasin Y,
Amar M, Fixler R, Battler A, Eldar M and Hasin D: Cytotoxic T
lymphocytes are activated following myocardial infarction and can
recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol.
32:2141–2149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Panizzi P, Swirski FK, Figueiredo JL,
Waterman P, Sosnovik DE, Aikawa E, Libby P, Pittet M, Weissleder R
and Nahrendorf M: Impaired infarct healing in atherosclerotic mice
with Ly-6C(hi) monocytosis. J Am Coll Cardiol. 55:1629–1638. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sager HB, Hulsmans M, Lavine KJ, Moreira
MB, Heidt T, Courties G, Sun Y, Iwamoto Y, Tricot B, Khan OF, et
al: Proliferation and recruitment contribute to myocardial
macrophage expansion in chronic heart failure. Circ Res.
119:853–864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao J, Li X, Hu J, Chen F, Qiao S, Sun X,
Gao L, Xie J and Xu B: Mesenchymal stromal cell-derived exosomes
attenuate myocardial ischemia-reperfusion injury through
miR-182-regulated macrophage polarization. Cardiovasc Res.
115:1205–1216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prabhu SD: It takes two to tango: Monocyte
and macrophage duality in the infarcted heart. Circ Res.
114:1558–1560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Frangogiannis NG, Mendoza LH, Lindsey ML,
Ballantyne CM, Michael LH, Smith CW and Entman ML: IL-10 is induced
in the reperfused myocardium and may modulate the reaction to
injury. J Immunol. 165:2798–2808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Prabhu SD and Frangogiannis NG: The
biological basis for cardiac repair after myocardial infarction:
From inflammation to fibrosis. Circ Res. 119:91–112. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang Z, Day YJ, Toufektsian MC, Xu Y,
Ramos SI, Marshall MA, French BA and Linden J: Myocardial
infarct-sparing effect of adenosine A2A receptor activation is due
to its action on CD4+ T lymphocytes. Circulation. 114:2056–2064.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Iwata M, Cowling RT, Yeo SJ and Greenberg
B: Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to
treat cardiac remodeling and heart failure. J Mol Cell Cardiol.
51:542–547. 2011. View Article : Google Scholar
|
|
42
|
Song Q, Liu L, Yu J, Zhang J, Xu M, Sun L,
Luo H, Feng Z and Meng G: Dihydromyricetin attenuated Ang II
induced cardiac fibroblasts proliferation related to inhibitory of
oxidative stress. Eur J Pharmacol. 807:159–167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iwata M, Cowling RT, Gurantz D, Moore C,
Zhang S, Yuan JX and Greenberg BH: Angiotensin-(1-7) binds to
specific receptors on cardiac fibroblasts to initiate antifibrotic
and antitrophic effects. Am J Physiol Heart Circ Physiol.
289:H2356–H2363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Basu R, Poglitsch M, Yogasundaram H,
Thomas J, Rowe BH and Oudit GY: Roles of angiotensin peptides and
recombinant human ACE2 in heart failure. J Am Coll Cardiol.
69:805–819. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shatanawi A, Romero MJ, Iddings JA,
Chandra S, Umapathy NS, Verin AD, Caldwell RB and Caldwell RW:
Angiotensin II-induced vascular endothelial dysfunction through
RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase
pathway. Am J Physiol Cell Physiol. 300:C1181–C1192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Du M, Huang K, Gao L, Yang L, Wang WS,
Wang B, Huang K and Huang D: Nardosinone protects H9c2 cardiac
cells from angiotensin II-induced hypertrophy. J Huazhong Univ Sci
Technolog Med Sci. 33:822–826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Wang Y, Shen W, Ma S, Chen W and
Qi R: Rosa rugosa flavonoids alleviate myocardial ischemia
reperfusion injury in mice by suppressing JNK and p38 MAPK.
Microcirculation. 24:2017. View Article : Google Scholar
|
